Skip to content
Immunexpress
  • Home
  • About Us
    • About Immunexpress
    • Executive Team
    • Board Of Directors
    • Careers
  • About Sepsis
    • The Sepsis Problem
    • Partnership with Sepsis Alliance
    • External Resources
  • About SeptiCyte®
    • SeptiCyte™ RAPID
    • Host Response
    • SeptiCyte™ LAB
  • Validation
    • Clinical Validation
    • Publications
    • Collaborators
  • Newsroom
  • Contact Us
Immunexpress
  • Home
  • About Us
    • About Immunexpress
    • Executive Team
    • Board Of Directors
    • Careers
  • About Sepsis
    • The Sepsis Problem
    • Partnership with Sepsis Alliance
    • External Resources
  • About SeptiCyte®
    • SeptiCyte™ RAPID
    • Host Response
    • SeptiCyte™ LAB
  • Validation
    • Clinical Validation
    • Publications
    • Collaborators
  • Newsroom
  • Contact Us

Archive for November 2018

Sepset’s Sepsis Signature

By Helene Kuhn | November 16, 2018

BioCentury Senior Writer Michael Leviten discusses gene expression tests that could speed up diagnosis of sepsis.

Read More

About Us

Immunexpress is a privately-owned group of companies developing and commercializing revolutionary molecular diagnostics to aid clinicians in managing patients with, or suspected of, sepsis through analysis of molecular blood biomarkers from a patient’s immune system (the ‘host response’).

Additional Resources

Newsroom

Contact Us

Privacy policy

 

Tweets by @Immunexpress

© 2023 Immunexpress Inc. — all Rights Reserved.
425 Pontius Avenue North, Suite 470, Seattle, WA 98109 USA
+1 206.858.6436 – info@immunexpress.com

𝕏
Scroll To Top
We use cookies to ensure that we give you the best experience on our website. Continuing to use this website means you're ok with this. For more information about how we use cookies see our privacy policy.OkNoPrivacy policy
You can revoke your consent any time using the Revoke consent button.Revoke cookies